key: cord-0052297-ygtbuy4k
authors: nan
title: Corrigenda
date: 2020-11-04
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.08.023
sha: 13681c257a35e968b5b0d81f2a3f43f6011c3e5f
doc_id: 52297
cord_uid: ygtbuy4k

nan

corticosteroids on COVID-19 outcomes. This is highlighted by preliminary findings in a recent study demonstrating the efficacy of dexamethasone in reducing mortality in critically ill patients with COVID-19, but showing no benefit in those not requiring respiratory support. 4 Furthermore, our study 5 demonstrated a ''dose-response,'' with greater degrees of respiratory allergy being associated with larger reductions in angiotensin-converting enzyme 2 gene expression in the nasal epithelium, and the impact of suppressing type 2 inflammation in these individuals is not currently known. Thus, we agree that strategies targeting the upper airway for the prevention and/or treatment of COVID-19 are of significant interest. Studies with nasal/inhaled corticosteroids as postexposure prophylaxis for very early stages of the disease (prehospitalization) may be worth considering. Furthermore, various additional approaches are available for consideration, including topical therapy with intranasal antivirals, immune stimulants, and/or vaccines. 

COVID-19: start with the nose

SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract

Detection of rhinovirus RNA in lower airway cells during experimentally induced infection

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

), it has been brought to the Editors' attention that the authors' names were incorrect as printed. The names were shown as Gregori Silvia, PhD, and Aiuti Alessandro, MD, PhD. The first and last names of both authors were inadvertently reversed and should be Silvia Gregori